Menu Search
Equities

Novartis AG

NOTA:DUS

Novartis AG

Actions
  • Price (EUR)70.50
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-14.80%
  • Beta0.4781
Data delayed at least 15 minutes, as of Aug 04 2020 07:20 BST.
More ▼

Profile data is unavailable for this security.

About the company

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

  • Revenue in USD (TTM)49.53bn
  • Net income in USD7.21bn
  • Incorporated1996
  • Employees110.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVN:VTX since
announced		Transaction
value
Amblyotech IncDeal completed20 Apr 202020 Apr 2020Deal completed-10.45%--
The Medicines CoDeal completed24 Nov 201924 Nov 2019Deal completed-14.22%7.38bn
Data delayed at least 15 minutes, as of Aug 04 2020 10:05 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.